Prostate Cancer: Early Warning Signs, Screening, and Treatments You Should Know

In India, prostate cancer is the second most common cancer among men after oral cancer, and its incidence has been rising steadily particularly in urban populations and men over 50. What makes it both challenging and, in many cases, very manageable is the same thing: it usually grows slowly, often without any symptoms in its early stages. Most men who are eventually diagnosed had no idea anything was wrong.

That silence is what makes awareness matter. Prostate cancer caught at Stage 1 or 2 has survival rates above 95%. Caught at Stage 4, after it has spread to the bones or distant organs, the picture changes substantially. The difference, in most cases, comes down to whether a man knew what to watch for and whether he went for screening when he should have.

What Is the Prostate and How Does Prostate Cancer Develop?

The prostate is a small walnut-sized gland that sits just below the bladder in men, surrounding the urethra the tube that carries urine and semen out of the body. Its primary function is to produce seminal fluid, which nourishes and transports sperm.

Prostate cancer develops when cells in the prostate begin to grow abnormally and uncontrollably. Most prostate cancers begin in the glandular cells of the peripheral zone the outer region of the prostate and are classified as adenocarcinomas. Because the prostate surrounds the urethra, even a slow-growing tumour can eventually affect urinary function as it enlarges.

What distinguishes prostate cancer from many other cancers is its range of behaviour. Some prostate cancers are so slow-growing that they never cause symptoms or threaten life. Others are aggressive, spread quickly, and require immediate treatment. The Gleason score a grading system based on how abnormal the cancer cells look under a microscope helps doctors determine which category a particular cancer falls into, and shapes all subsequent treatment decisions.

Causes and Risk Factors of Prostate Cancer

No single cause explains why prostate cancer develops, but several factors are consistently associated with elevated risk.

Age is the most significant. Prostate cancer is rare before 40, but risk increases sharply after 50. The majority of diagnoses in India occur in men between 60 and 75. This doesn’t mean younger men are immune — it means the case for regular screening becomes compelling from age 50 onwards, and earlier for those with additional risk factors.

Family history matters significantly. A man with a father or brother diagnosed with prostate cancer has roughly double the average risk. If multiple first-degree relatives were affected, or if relatives were diagnosed young, that risk is higher still. Inherited mutations in the BRCA1 and BRCA2 genes the same mutations associated with breast and ovarian cancer in women also raise prostate cancer risk in men, particularly for more aggressive disease.

Diet and lifestyle play a contributing role. Diets high in red meat and processed foods and low in vegetables have been associated with higher prostate cancer rates across multiple population studies. Obesity, particularly excess abdominal fat, is associated with more aggressive tumour biology. Smoking is associated with higher risk of fatal prostate cancer specifically.

Ethnic background is a documented risk factor internationally men of African descent have consistently higher incidence and mortality rates globally, a disparity that is not fully explained by access to care alone.

Early Warning Signs of Prostate Cancer

Early prostate cancer typically causes no symptoms at all which is why screening exists. Symptoms appear when the tumour has grown large enough to press on the urethra or has spread beyond the prostate. By the time symptoms develop, the cancer has usually progressed beyond its earliest, most treatable stage.

That said, these are the warning signs that deserve prompt medical attention:

Difficulty urinating is the most common symptom a weak or interrupted urine stream, difficulty starting urination, or a sense that the bladder hasn’t fully emptied. These symptoms can also be caused by benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate that is very common in older men. The overlap in symptoms is exactly why a medical evaluation rather than self-diagnosis is important the cause needs to be properly identified.

Frequent urination, particularly at night (nocturia), is another common symptom shared with BPH. When this pattern is new, progressive, and not easily explained, it warrants investigation.

Blood in urine or semen haematuria or haematospermia should always be evaluated medically. While both have multiple possible causes, their presence alongside urinary symptoms or in a man over 50 should prompt a PSA test and clinical examination.

Unexplained pain in the lower back, hips, or pelvis particularly if it is persistent, deep, and doesn’t follow a clear musculoskeletal pattern can indicate cancer that has spread to nearby bones. Bone pain is a later symptom, but it is one of the more commonly reported presenting complaints in men who are diagnosed at an advanced stage in India, where late presentation remains a significant clinical challenge.

Painful ejaculation and erectile dysfunction developing rapidly and without other explanation can, in some cases, be associated with prostate cancer affecting nearby structures, though both symptoms have many other causes.

Prostate Cancer Screening: Who Should Get Tested and When

Screening is what finds prostate cancer before symptoms develop at the stage when treatment is most effective and least disruptive.

The PSA (Prostate-Specific Antigen) blood test measures the level of a protein produced by prostate cells. Elevated PSA is not a diagnosis of cancer it can be raised by BPH, prostatitis, or even vigorous physical activity. But consistently elevated or rising PSA levels are a signal that further investigation is needed. Men at average risk should discuss PSA screening with their doctor from age 50. Men with a family history of prostate cancer or known BRCA mutations should consider starting the conversation at 45.

The Digital Rectal Examination (DRE) involves the doctor manually examining the prostate through the rectum to feel for abnormalities in size, shape, or texture. It remains a useful clinical tool and is typically performed alongside PSA testing rather than as a standalone assessment.

PSA and DRE are screening tools not diagnostic ones. An abnormal result from either leads to further investigation, not an immediate diagnosis.

How Prostate Cancer Is Diagnosed

When PSA levels are elevated or a DRE raises concern, the diagnostic pathway typically involves the following:

A prostate biopsy is the definitive way to confirm prostate cancer. A needle guided by transrectal ultrasound takes multiple small tissue samples from different parts of the prostate. These samples are examined under a microscope, and if cancer is present, the Gleason score is assigned based on how abnormal the cells look. A higher Gleason score indicates more aggressive cancer behaviour.

MRI of the prostate specifically multiparametric MRI (mpMRI) has become increasingly used before biopsy to identify areas of suspicion within the prostate and guide the biopsy needle more precisely. This reduces the number of unnecessary biopsies and improves detection of clinically significant cancers.

Bone scan, CT scan, and PET scan are used when there is concern that the cancer has spread beyond the prostate to nearby lymph nodes, bones, or distant organs. These imaging tests establish the stage of the disease and determine how extensive treatment needs to be.

Stages of Prostate Cancer

Stage 1

Prostate cancer is confined to the prostate, involves a small area, and has a low Gleason score. It is highly treatable, and in many cases, active surveillance rather than immediate treatment is appropriate.

Stage 2

Prostate cancer is still confined to the prostate but is larger or has a higher Gleason score, indicating more aggressive biology. Surgery or radiation therapy is typically recommended.

Stage 3

Prostate cancer has spread beyond the outer layer of the prostate to nearby tissues or seminal vesicles. Treatment typically combines radiation with hormone therapy.

Stage 4

Prostate cancer has spread to nearby lymph nodes, bones, or distant organs. Treatment at this stage focuses on controlling the disease and maintaining quality of life. Modern hormone therapies, chemotherapy, and targeted agents have extended survival meaningfully in Stage 4 disease over the past decade.

Treatment Options for Prostate Cancer

Treatment depends on the cancer’s stage, Gleason score, PSA level, the patient’s age, overall health, and personal priorities including fertility and quality of life considerations.

Active surveillance is appropriate for low-risk, slow-growing cancers particularly in older men or those with other significant health conditions. It involves regular PSA tests, DRE, and repeat biopsies at defined intervals to monitor for any signs of progression. It is not the same as doing nothing it is a deliberate, monitored approach that avoids the side effects of treatment in men whose cancer is unlikely to progress significantly.

Surgery in the form of radical prostatectomy removing the entire prostate gland is a standard treatment for localised prostate cancer in men who are fit for surgery. Robotic-assisted laparoscopic prostatectomy has become the preferred approach at most major Indian cancer centres, offering better precision, reduced blood loss, and faster recovery compared to open surgery. Nerve-sparing techniques, where possible, reduce the risk of post-surgical erectile dysfunction and urinary incontinence.

Radiation therapy is an alternative to surgery for localised and locally advanced prostate cancer. External beam radiation therapy (EBRT) delivers targeted radiation to the prostate over several weeks. Brachytherapy involves implanting radioactive seeds directly into the prostate for internal radiation delivery. Both approaches are effective alternatives to surgery, particularly for men who are not surgical candidates or who prefer to avoid an operation.

Hormone therapy also called androgen deprivation therapy (ADT) works by reducing the levels of male hormones (androgens) that fuel prostate cancer cell growth. It is used alongside radiation for locally advanced disease, as initial treatment for metastatic disease, and when cancer recurs after initial treatment. Modern hormone therapy drugs including enzalutamide and abiraterone have significantly improved outcomes in advanced prostate cancer.

Chemotherapy is used primarily in metastatic prostate cancer that has become resistant to hormone therapy a state called castration-resistant prostate cancer (CRPC). Docetaxel and cabazitaxel are the main agents used.

Focal therapies including High Intensity Focused Ultrasound (HIFU) and cryotherapy are being used at select centres for carefully chosen cases targeting only the cancerous area of the prostate rather than the whole gland, with the aim of reducing treatment side effects.

Prostate Cancer Myths Cleared Up

Myth: Only older men get prostate cancer.
Risk increases with age, and most diagnoses occur after 60. But prostate cancer does occur in younger men — particularly those with a family history or inherited BRCA mutations. Age is a risk factor, not a guarantee, and it is not a reason for younger men with symptoms to delay evaluation.

Myth: A high PSA always means cancer.
PSA can be elevated for multiple reasons — BPH, prostatitis, recent sexual activity, or even vigorous cycling. An elevated PSA is a reason to investigate further, not a diagnosis. Conversely, some aggressive prostate cancers can occur with relatively normal PSA levels. PSA is a useful tool with real limitations — it works best as part of an ongoing monitoring conversation with a doctor, not as a single test interpreted in isolation.

Myth: Prostate cancer always causes symptoms.
Early prostate cancer almost never causes symptoms. This is the most important misconception to correct — it is precisely why screening exists, and why waiting for symptoms before getting tested means waiting until the cancer has already progressed.

Prevention Options for Prostate Cancer

No intervention eliminates prostate cancer risk entirely, but several lifestyle factors are associated with lower risk. A diet high in vegetables particularly cruciferous vegetables like broccoli and cauliflower and low in red and processed meat is consistently associated with lower prostate cancer rates across population studies. Maintaining a healthy weight, exercising regularly, and avoiding smoking all contribute to lower risk of aggressive prostate cancer specifically. Men with a family history of prostate or BRCA-related cancers should discuss genetic counselling and earlier screening timelines with their doctor.

When Should You See a Doctor?

If you are over 50 and haven’t discussed PSA screening with your doctor that conversation is overdue. If you have a family history of prostate cancer or known BRCA mutations, start that conversation at 45.

See a doctor promptly if you notice difficulty urinating, a weak or interrupted urine stream, blood in urine or semen, unexplained pelvic or lower back pain, or any rapid change in urinary patterns.

An online oncologist consultation through HealthPil is available for PSA result interpretation, second opinions on diagnosis, treatment planning guidance, and specialist advice from home.

How HealthPil Can Help

HealthPil connects men and their families with experienced urologists and oncologists for prostate cancer screening guidance, diagnosis support, treatment planning, and second opinions. Whether you have a concerning PSA result, have been recently diagnosed, or want to understand your screening options expert help is available online.

Book your online consultation with HealthPil today.

Summary

Prostate cancer is the second most common cancer in Indian men and is highly treatable when caught early  with survival rates above 95% at Stage 1. Most early prostate cancers cause no symptoms, which is why PSA screening from age 50 is important. Warning signs that do appear include difficulty urinating, frequent nighttime urination, blood in urine or semen, and unexplained pelvic or bone pain. Diagnosis involves PSA testing, DRE, MRI, and prostate biopsy with Gleason scoring. Treatment options range from active surveillance for low-risk disease to robotic surgery, radiation therapy, hormone therapy, and chemotherapy depending on stage and cancer biology. Family history and BRCA mutations are important risk factors that warrant earlier screening conversations.